Download PDF
Arthritis und Rheuma 2019; 39(01): 28-36
DOI: 10.1055/a-0828-4338
Schwerpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Antinukleäre Antikörper

Beschreibung der Fluoreszenzmuster entsprechend der neuen ICAP-NomenklaturAntinuclear AntibodiesDescription of ANA Patterns according to the ICAP Nomenclature
Verena Jansen
1   LADR Laborzentrum an den Immanuel Kliniken, MVZ Laborverbund GmbH, Hennigsdorf bei Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
13 March 2019 (online)

    Permissions and Reprints

Zusammenfassung

Bei der Diagnose und Klassifikation systemischer autoimmuner rheumatischer Erkrankungen kommt dem positiven Nachweis Antinukleärer Antikörper (ANA) große Bedeutung zu. Als methodischer Goldstandard hat sich der Indirekte Immunfluoreszenztest (IIFT) unter Verwendung der HEp2-Zelle als Substrat durchgesetzt, mit dem bei Vorliegen von ANA charakteristische Fluoreszenzmuster mikroskopisch unterschieden werden können. Um ANA-Befunde besser vergleichen zu können, wurde von einer internationalen Initiative, dem International Consensus on Antinuclear Antibody Patterns (ICAP), ein Standard entwickelt, mit dem die Muster beschrieben und nummeriert werden. Die Zielsetzung der ICAP-Initiative, die neue Nomenklatur, Maßnahmen der Qualitätssicherung und noch offene Fragen sollen hier vorgestellt werden.

Abstract

Antinuclear antibodies (ANA) are essential markers for the diagnosis of systemic autoimmune rheumatic diseases. Indirect Immunofluorescence (IIF) using the substrate HEp2 cells is the gold standard method for their detection. The IIF can be used to microscopically distinguish characteristic fluorescence patterns in the presence of ANA. To better compare ANA findings, an international initiative, the International Consensus on Antinuclear Antibody Patterns (ICAP), has developed a standard that describes and numbers the patterns. The objective of the ICAP initiative, the new nomenclature, quality assurance measures and remaining issues will be presented here.

Schlüsselwörter:

Antinukleäre Antikörper - Indirekte Immunfluoreszenz - Fluoreszenzmuster - ICAP

Keywords

Antinuclear antibodies - indirect immunofluorescence patterns - ICAP
 

  • Literatur

  • 1 Petri M, Orbai AM, Alarcon GS. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.. Arthritis Rheum 2012; 64: 2677-2686.
    CrossrefPubMedGoogle Scholar
  • 2 Simard JF, Costenbader KH. Epidemiology and classification of systemic lupus erythematodes.. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Hrsg. Rheumatology (6th edition). Philadelphia: Elsevier; 2015: 1021-1025
    Google Scholar
  • 3 Shiboski CH, Shiboski SC, Seror R. et al. American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patients cohorts.. Arthritis Rheumatol 2017; 69: 35-45.
    CrossrefPubMedGoogle Scholar
  • 4 van den Hoogen F, Khanna D, Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.. Ann Rheum Dis 2013; 72 (Suppl. 11) 1747-1755.
    CrossrefPubMedGoogle Scholar
  • 5 Andréasson K, Saxne T, Bergknut C. et al. Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria.. Ann Rheum Dis. 2014; 73 (Suppl. 10) 1788-1792.
    CrossrefPubMedGoogle Scholar
  • 6 LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis.. J Rheumatol 2001; 28: 1573-1576.
    Google Scholar
  • 7 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts).. N Engl J Med 1975; 292 (Suppl. 07) 344-347.
    CrossrefPubMedGoogle Scholar
  • 8 Troyanov Y, Targoff IN, Tremblay JL. et al. Novel classification of idiopathic inflammatory myopathies based on Overlap Syndrome features and autoantibodies.. Analysis of 100 French Canadian Patients. Medicine 2005; 84 (Suppl. 04) 231-249.
    PubMedGoogle Scholar
  • 9 Tanimoto K, Nakano K, Kano S. et al. Classification criteria for polymyositis and dermatomyositis.. The Journal of rheumatology 1995; 22: 668-674.
    PubMedGoogle Scholar
  • 10 Lundberg IE, Tjärnlund A, Bottai M. et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.. Annals of the rheumatic diseases 2017; 76: 1955-1964.
    CrossrefPubMedGoogle Scholar
  • 11 Sharp GC. Diagnostic criteria for classification of MCTD.. In: Kasukawa R, Sharp GC. Hrsg. Mixed Connective Tissue Disease and Antinuclear Autoantibodies.. Amsterdam: Elsevier; 1987: 23-32.
    Google Scholar
  • 12 Alarcón-Segovia D, Vilarreal M. Classification and diagnostic criteria for mixed connective tissue disease.. In: Kasukawa R, Sharp GC. Hrsg. Mixed Connective Tissue Disease and Anti-Nuclear Antibodies.. Amsterdam: Elsevier; 1987: 33-40.
    Google Scholar
  • 13 Meroni PL, Schur PH. ANA screening: an old test with new recommendations.. Annals of the Rheumatic Diseases 2010; 69 (Suppl. 08) 1420-1422.
    CrossrefPubMedGoogle Scholar
  • 14 Hahon N, Eckert HL, Stewart J. Evaluation of cellular substrates for antinuclear antibody determinations.. Journal of Clinical Microbiology 1975; 2 (Suppl. 01) 42-45.
    PubMedGoogle Scholar
  • 15 Richtlinie der Bundesärztekammer (RiLiBÄK) zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen - Gemäß dem Be-schluss des Vorstands der Bundesärztekammer vom 11.04.2014 und 20.06.2014.. Deutsches Ärzteblatt 2014; 38: 1583-1618.
    Google Scholar
  • 16 DIN EN ISO 15189 Medizinische Laboratorien - Anforderungen an die Qualität und Kompetenz. Korrigierte Fassung 2014-08-15
  • 17 DAkkS - Beschlüsse des Sektorkomitees Medizinische Laboratorien zu Anforderungen der DIN EN ISO 15189:2014 an die Qualität und Kompetenz von Medizinischen Laboratorien 71 SD 3 025 | Revision: 1.4 | 17. November 2017 5.6-03 Sicherstellung der Vergleichbarkeit von Ergebnissen bei Verfahren mit subjektiver Bewertung
  • 18 DAkkS - Beschlüsse des Sektorkomitees Medizinische Laboratorien zu Anforderungen der DIN EN ISO 15189:2014 an die Qualität und Kompetenz von Medizinischen Laboratorien 71 SD 3 025 | Revision: 1.4 | 17. November 2017 5.3-04: Vergleich quantitativer Methoden beim Wechsel von Geräten oder Reagenzien-Kits
  • 19 Chan EKL, Damoiseaux J, Carballo OG. et al. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015. Front Immunol 2015; 1-43
  • 20 Chan EKL, Damoiseaux J, de Melo Cruvinel W. et al. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015.. Lupus 2016; 25 (Suppl. 08) 797-804.
    CrossrefPubMedGoogle Scholar
  • 21 Chan E, Damoiseaux J, Carballo OG. et al. The international consensus on standardized nomenclature on antinuclear antibody HEp2-Cell patterns (ICAP) Initiative - Its impact and update from 3rd ICAP.. Lupus 2017; 4 (Suppl. 01) A1-A227.
    Google Scholar
  • 22 Chan EKL, Damoiseaux J, Carballo G. et al. The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative - Update and its Impact.. ACR/ARHP Annual Meeting 2016. Meeting Abstract
    Google Scholar
  • 23 Damoiseaux J, von Mühlen CA, Garcia-De La Torre I. et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results.. Autoimmun Highlights 2016; Dec 7 (Suppl. 01) 1-23.
    CrossrefPubMedGoogle Scholar
  • 24 Herold M, Klotz W, Sack U, Conrad K. ICAP - ein Versuch zur einheitlichen Beschreibung der Fluoreszenzmuster von antizellulären Antikörpern auf HEp2-Zellen.. J Lab Med 2017; 41 (Suppl. 04) 167-172.
    Google Scholar
  • 25 Naides SJ, Genzen J, Abel G. et al. Variability in ICAP (International Consensus on ANA Patterns) pattern reporting in testing for antinuclear antibodies (ANA) by indirect immunofluorescence assay (IFA).. 2017 ACR/ARHP Annual Meeting. Abstract Number 701
    Google Scholar
  • 26 Andrade LEC, Klotz W, Herold M. et al. International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I.. Clinical Chemistry and Laboratory Medicine 2018; 56 (Suppl. 10) 1783-1788.
    CrossrefPubMedGoogle Scholar
  • 27 Bentow C, Fritzler MJ, Mummert E, Mehler M. Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey.. Autoimmun Highlights 2016; 7 (Suppl. 01) 1-7.
    CrossrefPubMedGoogle Scholar
  • 28 Ghirardello A, Bassi N, Palma L. et al. Autoantibodies in polmyositis and dermatomyositis.. Curr Rheumatol Rep 2013; 15 (Suppl. 06) 335-344.
    CrossrefPubMedGoogle Scholar
  • 29 Triantafyllias K, Lütgendorf F. Muskelschmerz.. arthritis + rheuma 2018; 38: 185-194.
    Google Scholar
  • 30 Herold M, Klotz W, Andrade LEC. et al. International Consensus on Antinuclear Antibody Patterns: Defining negative results and reporting unidentified patterns.. Clinical Chemistry and Laboratory Medicine 2018; 56 (Suppl. 10) 1-4.
    CrossrefPubMedGoogle Scholar